Pfizer’s Zyrtec Remains Strong As Rx Antihistamine Market Weakens
This article was originally published in The Tan Sheet
Executive Summary
The many loratadine products now available in the OTC market have not been able to undercut sales for Pfizer's Zyrtec (cetirizine), according to the company
You may also be interested in...
Pfizer Rounds Out Zyrtec Line With Chewable Tablet NDA Approval
Pfizer hopes to increase pediatric use of its Rx allergy drug Zyrtec (cetirizine) with new 5 mg and 10 mg chewable tablets formulations, to be available starting in late April and moving to full distribution in early summer
Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
Sales for Wyeth's Alavert (loratadine) totaled $81.6 mil. in 2003, its first full year on the market, following a significant drop in the fourth quarter
Allegra Faces Increasing Challenges In Rx Drug Arena
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis